Introduction {#Sec1}
============

Schizophrenia is a mostly chronic mental disorder, and symptomatic relapse is frequently observed during the course of the illness. It is often associated with social and/or occupational decline that can be difficult to reverse. Most patients with schizophrenia need long-term pharmacological treatment, and antipsychotic drugs represent the mainstay of clinical care \[[@CR1]\]. Long-acting injectable antipsychotics (LAIs) were developed in the 1960s and were originally thought to be particularly advantageous for patients with adherence problems and for those with a history of severe relapse upon medication discontinuation \[[@CR2]\]. The use of first-generation antipsychotic (FGA) LAIs has recently decreased since several new-generation antipsychotics (NGAs), including risperidone, olanzapine, paliperidone, and aripiprazole, have become available as long-acting formulations and new evidence has been accumulating. This article updates the information on the use of NGA LAIs in schizophrenia and discusses current issues from clinical perspectives. Information on the results of placebo-controlled registration trials of NGA LAIs is not detailed in this review, because all of them have demonstrated a significant positive impact on relapse rates and symptoms over placebo in patients with chronic schizophrenia as well as in acutely ill patients \[[@CR3], [@CR6]••\].

General considerations {#Sec2}
======================

Here, we provide considerations pertaining to all available agents. More specific findings concerning the individual drugs are reviewed in the respective chapters.

Efficacy of LAIs versus oral antipsychotics {#Sec3}
===========================================

Meta-analyses of randomized controlled trials (RCTs) comparing NGA LAIs with either placebo or oral antipsychotics (OAPs) have provided discrepant results. While NGA LAIs have consistently demonstrated greater efficacy than placebo, significant differences compared with OAPs are much less evident \[[@CR5], [@CR7]--[@CR9]\]. However, RCTs might not be the best strategy to evaluate the efficacy of LAIs because of selective recruitment as well as indirect compliance enhancing measures, such as frequent visits, and increased encouragement to stay in studies and thereby on treatment \[[@CR4], [@CR10], [@CR11]\].

Mirror image studies comparing periods of treatment with LAIs versus OAPs in the same patients might better reflect the impact of LAIs in a real-world setting \[[@CR11]\]. A meta-analysis of 25 mirror image studies of LAIs (*n* = 5940) demonstrated superiority of LAIs over OAPs in preventing a next hospitalization \[[@CR11]\]. Cohort studies show mixed results, but most of them report better outcomes for LAIs than for OAPs \[[@CR10], [@CR12]--[@CR14]\]. In a meta-analysis that included 58 studies with both interventional and non-interventional designs, using meta-regression analyses, LAIs were superior to NGA OAPs in reducing hospitalization rates \[[@CR15]\]. In cohort studies, however, time order effects, prescribing bias and lack of blinding. may affect outcomes \[[@CR6]••, [@CR10]\]. Moreover, no reverse mirror image studies such as switching from LAIs to OAPs have been conducted \[[@CR16]\].

Each of the study designs has methodological limitations; thus, further prospective longer term large pragmatic trials designed to reflect everyday clinical practice are necessary to evaluate the efficacy of LAIs versus OAPs.

Safety and tolerability of LAIs versus oral antipsychotics {#Sec4}
==========================================================

In a recent meta-analysis of 16 RCTs comparing the same antipsychotics, LAIs and OAPs did not significantly differ with respect to the frequency of treatment discontinuation due to adverse events, serious adverse events, or all-cause death \[[@CR17]•\]. There were also no differences between LAIs and OAPs in extrapyramidal symptoms (EPSs) except for akinesia, as well as for weight gain and all metabolic adverse events except for LDL-cholesterol. However, another meta-analysis of NGA LAIs showed a greater risk of EPS with NGA LAIs than with OAPs \[[@CR5]\]. NGA LAIs and OAPs were associated with similar risks of metabolic adverse events, suggesting that pharmacokinetic differences between the two preparations are irrelevant to this adverse event profile \[[@CR18]\]. On the other hand, LAIs showed a significantly lower change in serum prolactin levels compared with OAPs \[[@CR17]•\]. In another recent meta-analysis of 52 RCTs, there was no significant difference between LAIs and OAPs with respect to all-cause death and death due to suicide \[[@CR19]\].

Compared with OAPs, the pharmacokinetics of LAIs such as the long elimination half-life can delay both the onset and the remission of adverse effects \[[@CR18]\]. However, few studies have compared NGA LAIs with OAPs in terms of adverse event severity and time course. Moreover, studies on adverse events for NGA LAIs after the discontinuation of supplemental oral antipsychotics are required \[[@CR17]•\].

Efficacy of LAIs versus LAIs {#Sec5}
============================

Only a few direct comparisons between one LAI and another have been conducted \[[@CR20]--[@CR23], [@CR24]•\]. These indicate that relapse rates and symptom improvement are similar with different LAIs including FGA LAIs and NGA LAIs \[[@CR6]••\]. At present, there appears to be no advantage of one LAI over another in general efficacy. Differences among LAIs were observed in some other efficacy and safety domains as described below. Further prospective large head-to-head comparison studies of different LAIs are warranted.

Specific agents {#Sec6}
===============

Risperidone LAI {#Sec7}
---------------

Risperidone LAI (RLAI) was introduced as the first NGA LAI in 2003. It is a microsphere preparation, and biweekly dosing intervals are needed \[[@CR4]\]. Oral supplementation at the time of starting is required for 3 weeks. Its approval was based on three pivotal trials \[[@CR25]--[@CR27]\], which demonstrated advantages over placebo, comparable efficacy to oral risperidone, and acceptable long-term safety. It has been widely used since. It failed to differentiate from psychiatrists' choice of oral antipsychotics in a large-scale single-blind comparative study conducted in the US Veterans Administration system regarding hospitalization rates \[[@CR28]\].

On the other hand, in the previously cited cohort study in Finland, the authors found a significantly lower risk of rehospitalization on depots than on oral drugs \[[@CR13]\], while in yet another nationwide retrospective inception cohort study in Denmark, RLAI and FGA LAIs did not differ regarding time to hospitalization, all-cause discontinuation, or duration of hospitalization in patients with schizophrenia \[[@CR23]\]. However, this study did not evaluate psychopathology, functional outcomes, quality of life (QOL), or side effects.

Olanzapine pamoate {#Sec8}
------------------

Olanzapine pamoate LAI (OLAI) received marketing approval in 2008 in the EU and in 2009 in the USA \[[@CR4]\]. It is a crystalline salt formulation consisting of olanzapine and pamoic acid \[[@CR29]\]. Supplemental oral olanzapine is not necessary at the initiation of OLAI \[[@CR4]\].

In a 24-week double-blind RCT comparing OLAI with oral olanzapine in stable outpatients with schizophrenia, OLAI showed comparable efficacy and safety to oral olanzapine, except for injection-related adverse events \[[@CR30]\]. OLAI can induce post-injection delirium/sedation syndrome (PDSS) in a small proportion of patients \[[@CR29]\]. PDSS occurred in approximately 0.07% of injections and in 1.03% of patients in routine clinical practice \[[@CR31]\]. So far, there were no fatalities by PDSS, and most cases resolved within 72 h \[[@CR18]\]. OLAI must be administered in registered healthcare facilities, and all patients should be monitored for at least 3 h after injection \[[@CR29]\]. To date, studies to compare OLAI with other LAIs or other oral antipsychotics are lacking.

Once-monthly paliperidone palmitate {#Sec9}
-----------------------------------

Paliperidone palmitate (PP), a crystalline composition of 9-hydroxyrisperidone, is the first once-monthly NGA LAI available, and supplementation with oral paliperidone is not required after the injection. \[[@CR4]\]. It was approved for use in 2009 in the USA and the EU.

Several double-blind RCTs were conducted to compare the effectiveness of PP with other LAIs, including RLAI \[[@CR20], [@CR32]--[@CR35]\] and haloperidol decanoate (HPD) \[[@CR22]\], and indirectly compared to oral paliperidone extended release (ER) with respect to tardive dyskinesia risk \[[@CR36]\]. In general, the results demonstrated similar efficacy and safety outcomes when comparing PP to RLAI or oral paliperidone ER in patients with recently diagnosed schizophrenia, adult patients with chronic schizophrenia \[[@CR20], [@CR32], [@CR36]\], and patients with markedly to severely ill schizophrenia \[[@CR34]\]. However, in a 53-week RCT, PP was not as efficacious as RLAI, which may have been due to an inadequate initial dosing strategy, since modified \[[@CR33]\]. In patients with schizophrenia or schizoaffective disorder, PP was not superior to HPD in terms of prevention of efficacy failure \[[@CR22]\] although this study was hampered by a considerable dropout rate \[[@CR37]\]. Moreover, PP was associated with more weight gain and higher prolactin levels but showed a lower propensity to cause EPS than HPD.

Three-monthly paliperidone palmitate {#Sec10}
------------------------------------

Three-monthly paliperidone palmitate (3MPP) was approved for marketing in 2015 in the USA. It was superior to placebo in a relapse prevention study \[[@CR38]\]. In a 48-week double-blind non-inferiority RCT, 3MPP showed similar relapse rates compared with monthly PP (8 versus 9%) in patients with schizophrenia who were previously stabilized with monthly PP \[[@CR39]\]. The safety and tolerability profiles of the two formulations were also similar. The most common treatment-emergent adverse event was weight gain.

Aripiprazole LAI {#Sec11}
----------------

Aripiprazole LAI (ALAI) was approved for use in 2013. It is a lyophilized powder of aripiprazole, and oral antipsychotic supplementation is recommended for 2 weeks after the first injection \[[@CR29]\].

Its efficacy against relapses was demonstrated in a placebo-controlled 6-month trial \[[@CR40]\]. In two double-blind RCTs comparing ALAI with oral aripiprazole, ALAI was non-inferior to oral aripiprazole in patients with schizophrenia with respect to relapse risk and showed a comparable safety profile \[[@CR41], [@CR42]\]. In a phase IIIb, 28-week, open-label, head-to-head RCT, ALAI showed superior improvements over PP on health-related QOL and psychosocial functioning \[[@CR24]•\]. Moreover, ALAI demonstrated a more favorable safety profile compared with PP. This is the first evidence to show superiority of one NGA LAI over another.

Aripiprazole lauroxil became available in 2015 in the USA. It can be initiated in three different dosages and has the option of 6-week dosing \[[@CR43]\]. Oral aripiprazole supplementation is necessary for 3 weeks. It also showed robust efficacy for treating acute exacerbations of schizophrenia \[[@CR44]\].

LAI antipsychotics in early stages of schizophrenia {#Sec12}
---------------------------------------------------

The first 2--5 years after the onset of schizophrenia are considered to be critical in determining long-term prognosis \[[@CR45]\]. Poor adherence to oral medication is thought to be the most frequent cause of relapse \[[@CR46]\]. LAI antipsychotics may have a benefit in terms of managing adherence, thereby reducing relapse risk during early stages of the illness or in first-episode patients, a population that frequently shows non-adherence and relapses \[[@CR6]••, [@CR47]•\].

In an open-label RCT comparing the effectiveness of RLAI with oral NGAs in patients during the early phase of a schizophrenia spectrum disorder, no differences were observed for psychotic symptom control \[[@CR48]\]. Weiden et al. \[[@CR49], [@CR50]\] conducted a RCT in patients with first-episode schizophrenia and also found no difference in adherence between RLAI and OAPs. However, in a recent RCT comparing the effectiveness of RLAI with oral risperidone in patients with first-episode schizophrenia, RLAI showed better adherence, greater relapse prevention, and better symptom control than oral risperidone \[[@CR51]•\]. Similarly, Schreiner et al. \[[@CR52]\] compared once-monthly PP to various oral NGAs in a randomized open-label trial in recently diagnosed schizophrenia patients and found advantages of PP in terms of relapse prevention.

Evidence for other NGA LAIs is limited, and the proposal to recommend LAIs to patients with early stages or first-episode schizophrenia still debated \[[@CR53]--[@CR55]\]. When an LAI is administered for a patient with first-episode schizophrenia, safety and tolerability should firstly be evaluated with the oral equivalent and the LAI should be initiated at a low dose \[[@CR18]\]. Further studies examining the effects of early intervention with NGA LAIs on long-term outcome including cost-effectiveness are needed.

Discussion {#Sec13}
==========

Several NGAs have become available as long-acting formulations. Undoubtedly, NGA LAIs have extended the range of long-term therapeutic options for patients with schizophrenia. NGA LAIs appear not to confer a greater risk of serious adverse events, compared with OAPs \[[@CR17]•\]. It is important to note that NGA LAIs have different characteristics in terms of pharmacologic and pharmacokinetic profiles, cost, injection sites, needle gauge, injection volume, injection interval, dosage variation, storage needs, need for oral supplementation, observation period following injection, potential drug interactions, and adverse events \[[@CR6]••, [@CR29], [@CR54]\]. When using classical measures of psychopathology as endpoints, head-to-head studies have mostly demonstrated non-inferiority between different LAIs \[[@CR20], [@CR21]\]. Thus, when choosing an LAI, clinicians need to primarily consider side effect liability of the respective LAI. For example, potential concerns about the use of RLAI and PP are their propensity to cause EPS and hyperprolactinemia. OLAI has liability to induce weight gain, metabolic adverse events, and PDSS. ALAI appears to have advantages in terms of being essentially free of prolactin elevation or significant metabolic side effects \[[@CR29]\]. For clinicians, the appreciation of these differences is useful for selecting LAIs for the treatment of individual patients, especially also considering treatment history \[[@CR6]••, [@CR18]\].

Formulations with a longer dosing interval offer patients convenience regarding the frequency of injections and provide clinicians more time to intervene in case of adherence problems. However, Olfson et al. \[[@CR56]\] reported that early discontinuation of LAIs is quite common in the community treatment of schizophrenia. A great majority of patients starting LAIs discontinue use within the first few months of treatment. Thus, assuring a reliable therapeutic relationship between mental health professionals and patients through regular contact is particularly relevant for the successful treatment with LAIs on a 3-month schedule \[[@CR38], [@CR57]•\].

There are significant differences in LAI use across regions, countries, and over the years. Despite the available encouraging evidence, LAIs, at present, are not widely prescribed for a variety of reasons, including the reservations of patients, clinicians, and payers \[[@CR57]•\]. This is especially significant for patients in the early course of schizophrenia, where there are pro and con arguments for the use of LAIs \[[@CR53]--[@CR55]\]. Given the significance of continuous therapy in this critical period, physicians should consider all available treatment options, and the risk-benefit balance of LAI use needs to be thoroughly assessed for individual patients in a shared decision-making approach \[[@CR47]•, [@CR54]\]. Adequate education of mental health staff, patients, and families regarding the benefits and limitations of LAIs may reduce the negative image and prejudice towards the use of LAIs and increase acceptance within a strong therapeutic alliance \[[@CR6]••, [@CR47]•, [@CR57]•, [@CR58], [@CR59]\].

Conclusion {#Sec14}
==========

Recently introduced NGA LAIs broaden the options for the treatment of schizophrenia. However, current evidence regarding the effectiveness of NGA LAIs is still limited. For example, the question of whether NGA LAIs have advantages over FGA LAIs and/or oral antipsychotics is still open. Further head-to-head clinical trials comparing different LAIs in terms of efficacy, safety, functioning, and QOL under real-life treatment conditions are warranted to clarify the role of the individual LAIs in the long-term treatment of schizophrenia.
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